-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardio Diagnostics Secures Preliminary Medicare Payment Rates For Epi+Gen CHD And PrecisionCHD, Marking Key Reimbursement Milestone

Benzinga·07/22/2025 12:36:37
Listen to the news

Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™. A ‘gapfill' payment rate means that pricing is determined by each Medicare contractor, including MolDX, based on cost data from Cardio Diagnostics.

These preliminary payment rates, proposed as part of the calendar year 2025 gapfill pricing process, are expected to be finalized later this year and will be effective for claims with dates of service on or after January 1, 2025. The proposed rates represent a significant positive development in the Company's efforts to expand access to its advanced cardiovascular testing for Medicare beneficiaries.